Lack of FDA supervision, data on side effects hidden by companies resulted in severe autoimmune and mental complications Permission in 1960s to allow the technology was a “historical medical error”
REGN-COV2: Casirivimab and imdevimab
On November 21, 2020, the FDA
authorized the emergency use of REGN-COV2 for mild-to-moderate COVID-19. The EMA have concluded that healthcare professionals can use this treatment for COVID-19 patients at risk of developing severe disease but who do not require oxygen treatment. The agency will continue their rolling review to support national health authorities in European Union countries, who issue authorization for use individually.
The NIH, on the other hand, have stated that there is not enough evidence to support its use and that there is a need to review phase 3 trial data, which were released on March 23, 2021.